Table 3.
Anti-TB drug resistance, patients’ history of previous TB treatment and HIV status stratified for M. tuberculosis lineages
|
M.tuberculosis lineages (n) |
Anti-TB drugs resistance |
PT N (%) |
HIV + N (%) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| INH N (%) | RMP N (%) | STM N (%) | EMB N (%) | PZA N (%) | MDR N (%) | RFLD N (%) | |||
|
Dehli/CAS (95) |
10(10.0) |
3(3.3) |
10(10.5) |
7(7.4) |
2 (2.1) |
2 (2.1) |
2 (2.1) |
19 (20.0) |
24(25.3) |
|
Ethiopia_3 (32) |
10(31.0) |
3(9.4) |
6(18.8) |
5(15.6) |
4 (12.5) |
3(9.4) |
3(9.4) |
7(21.9) |
4(12.5) |
|
Haarlem (21) |
7(33.33) |
7(33.3) |
6(28.6) |
6(28.6) |
5 (23.8) |
7 (33.3) |
4 (19.0) |
2(9.5) |
7(33.3) |
|
Ethiopia_1 (19) |
1 (5.3) |
0 |
1(5.3) |
0 |
1(5.3) |
0 |
0 |
5 (26.3) |
4(21.1) |
|
Ethiopia_H37Rv like (17) |
2(11.8) |
0 |
1(5.9) |
0 |
0 |
0 |
0 |
3(17.6) |
6(35.3) |
|
Ethiopia_2 (9) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1(11.1) |
1(11.1) |
|
URAL (8) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 (37.5) |
|
LAM (8) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 (25.0) |
|
TUR (5) |
2 (40.0) |
0 |
1(20.0) |
0 |
0 |
0 |
0 |
1(20.0) |
2 (40.0) |
|
X-type (3) |
1(33.3) |
0 |
1(33.3) |
0 |
0 |
0 |
0 |
0 |
2(66.7) |
|
S-type (2) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Beijing (1) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
UgandII (1) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Not defined (23) |
1 (4.3) |
1(4.3) |
0 |
0 |
0 |
0 |
0 |
5(21.7) |
7(30.4) |
| Total (244) | 34 (13.9) | 14(5.7) | 26(10.7) | 18 (7.4) | 12 (4.9) | 12 (4.9) | 9(3.7) | 43(17.6) | 62(25.4) |
N= number, RFLD= Resistant to all first line anti-TB drugs, MDR= Multidrug resistant, LAM= M. tuberculosis Latin American Mediterranean, PT= previously treated cases, INH=isoniazid, RMP=rifampicin, STM= streptomycin, EMB= ethambutol, PZA= pyrazinamid, + = positive.